JP6018361B2 - 制御性t細胞活性を抑制するための、ヒトcd39に対する抗体およびその使用 - Google Patents
制御性t細胞活性を抑制するための、ヒトcd39に対する抗体およびその使用 Download PDFInfo
- Publication number
- JP6018361B2 JP6018361B2 JP2010544716A JP2010544716A JP6018361B2 JP 6018361 B2 JP6018361 B2 JP 6018361B2 JP 2010544716 A JP2010544716 A JP 2010544716A JP 2010544716 A JP2010544716 A JP 2010544716A JP 6018361 B2 JP6018361 B2 JP 6018361B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cells
- seq
- antibodies
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Description
本発明は、制御性T細胞(Treg)活性を抑制するための、ヒトCD39に対する抗体に関する。
制御性T細胞(Treg細胞)は、現在、それらの起源および抑制活性に応じて、2つの主要な部分集合に分類されている(Bluestone, J. A. & Abbas, A. K. Natural versus adaptive regulatory T cells. Nature Rev. Immunol. 3, 253-257 (2003))。内在性Treg細胞は、T−細胞受容体(TCR)と、胸腺ストロマにおいて発現した抗原との高親和性の相互作用によって、胸腺において発生する。これら内在性Treg細胞は、従来から、インビトロで、エフェクターT細胞の増殖を、接触依存的、かつ、サイトカイン非依存的に、抑制するものとして説明されている。内在性Treg細胞は、活性化リンパ球を特徴とする分子である、CD25、細胞傷害性Tリンパ球抗原4(CTLA4)、グルココルチコイド誘導性腫瘍壊死因子(TNF)受容体(GITR)およびOX40を構成的に発現する。しかしながら、少なくともマウス系では、転写因子FOXP3(フォークヘッドボックスp3)の高レベルの発現は、制御系統における最も際立ったマーカーである。今まで、不完全にしか特徴付けられていないが、内在性Treg細胞の抑制機構のネットワークは、CTLA4、膜結合性のトランスフォーミング成長因子(TGF)、および細胞周囲のアデノシンの産生といった表面分子を含む。
本発明は、増大した制御性T細胞(Treg)活性に関連付けられる疾病を治療または予防するためのCD39抗体に関する。
定義
「CD39」という語は、エクトヌクレオシド三リン酸塩ジホスホヒドロラーゼ−1(ENTPDl)とも呼ばれるCD39タンパク質を指す。CD39は、ATP/UTPおよびADP/UDPを、それぞれ、AMPなどのヌクレオシドに加水分解する外酵素である。
本願発明者は、BY40と呼ばれるCD39抗体を含む、CD39に対する抗体が、Treg活性を抑制することができることを証明した。ここに、本願発明者は、Treg活性を抑制するため、つまり、増大したTreg活性に関連付けられる疾病の治療または予防のための、CD39抗体の使用を提案する。
(i)CD39抗体を発現するハイブリドーマ(例えばCNCM-I-3889として寄託されたハイブリドーマ)を、抗体の発現を可能にするために適した条件下で培養するステップと、
(ii)発現された抗体を回復するステップとを含む。
本発明はまた、増大したTreg活性に関連付けられる疾病を治療または予防するための、CD39抗体を含む薬学的組成物に関する。
本発明は、ヒトCD39に対する、単離された抗体または該抗体のフラグメントを提供する。特に、本願発明者は、2008年1月4日に、マウスの CD39抗体 (BY40)を生成するハイブリドーマを、ブタペスト条約の条項に基づき、Collection Nationale de Cultures de Microorganismes (CNCM, Institut Pasteur, 25 rue du Docteur Roux, 75724 Paris Cedex 15, France)に寄託した。寄託したハイブリドーマのCNCM寄託番号は、I-3889である。
図1は、HIV-対照群およびHIV+患者群からのCD4+CD25lowおよびCD4+CD25highT細胞上のCD39の発現を示す図である。
HIV−対照群およびHIV+患者群からのCD4+CD251owおよびCD4+CD25high T細胞上のCD39の発現;
最近、マウスおよびヒトCD4+CD25high制御性T細胞は、エクトヌクレオチダーゼであるCD39を構成的に発現することが報告されている。エクトヌクレオチダーゼは、免疫活性化サイトで生成された細胞外ATPを変換し、細胞増殖の阻害剤であるアデノシンの生成を導く。ここで、我々は、抗CD39mAb BY40を用いて、HIV−対照群およびHIV+患者群からのCD4+CD251owおよびCD4+CD25high末梢血リンパ球(PBL)母集団におけるCD39の発現を検査した。図1からは、HIV−およびHIV+個体からのPBLでは、CD4+CD25high部分母集団内のCD39+細胞の割合が、CD4+CD251ow部分母集団内のCD39+細胞の割合よりも、著しく高い(p<0.01)ことが示されている(図1A)。平均は、16%対46%(HIV−)、および、17%対42%(HIV+)である。HIV-およびHIV+の群の間の母集団の同一のCD4+のそれぞれ比較した場合に、CD39+細胞間の割合に、統計上の差異は確認されなかった。
Bluestone, J. A. & Abbas, A. K. Natural versus adaptive regulatory T cells. Nature Rev. Immunol. 3, 253-257 (2003).
Brady G, Jantzen HM, Bernard HU, Brown R, Schutz G, Hashimoto-Gotoh T. New cosmid vectors developed for eukaryotic DNA cloning. Gene. 1984 Feb;27(2):223-32.
Caron PC, Laird W, Co MS, Avdalovic NM, Queen C, Scheinberg DA. Engineered humanized dimeric forms of IgG are more effective antibodies. J Exp Med. 1992 Oct 1;176(4): 1191-5.
Chardes T, Villard S, Ferrieres G, Piechaczyk M, Cerutti M, Devauchelle G, Pau B. Efficient amplification and direct sequencing of mouse variable regions from any immunoglobulin gene family. FEBS Lett. 1999 Jun 11;452(3):386-94.
Cole et al. "'Monoclonal Antibodies and Cancer Therapy'", Alan R. Liss, Inc., 1985, pp. 77-96.
Connolly DC, Bao R, Nikitin AY, Stephens KC, Poole TW, Hua X, Harris SS, Vanderhyden BC, Hamilton TC. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer. Cancer Res. 2003 Mar 15;63(6):1389-97.
Cote RJ, Morrissey DM, Houghton AN, Beattie EJ Jr, Oettgen HF, Old LJ. "Generation of human monoclonal antibodies reactive with cellular antigens". Proc Natl Acad Sci U S A. 1983 Apr;80(7):2026-30.
Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, Chen JF, Enjyoji K, Linden J, Oukka M, Kuchroo VK, Strom TB, Robson SC. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007 Jun l l;204(6): 1257-65. Epub 2007 May 14.
Edge AS, Faltynek CR, Hof L, Reichert LE Jr, Weber P. Deglycosylation of glycoproteins by trifluoromethanesulfonic acid. Anal Biochem. 1981 Nov 15;118(l):131-7.
Gazzano-Santoro H, Ralph P, Ryskamp TC, Chen AB, Mukku VR. A nonradioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody. J Immunol Methods. 1997 Mar 28;202(2): 163-71.
Gillies SD, Morrison SL, Oi VT, Tonegawa S. A tissue-specific transcription enhancer element is located in the major intron of a rearranged immunoglobulin heavy chain gene. Cell. 1983 Jul;33(3):717-28.
Koehler G., M. C. ( 1975) Nature 256, 495-497.
Kuwana Y, Asakura Y, Utsunomiya N, Nakanishi M, Arata Y, Itoh S, Nagase F, Kurosawa Y. Expression of chimeric receptor composed of immunoglobulin- derived V regions and T-cell receptor-derived C regions. Biochem Biophys Res Commun. 1987 Dec 31;149(3):960-8.
Mason JO, Williams GT, Neuberger MS. Transcription cell type specificity is conferred by an immunoglobulin VH gene promoter that includes a functional consensus sequence. Cell. 1985 Jun;41(2):479-87.
Miyaji H, Mizukami T, Hosoi S, Sato S, Fujiyoshi N, Itoh S. Expression of human beta-interferon in Namalwa KJM-I which was adapted to serum-free medium. Cytotechnology. 1990 Mar;3(2): 133-40.
Mizukami T, Itoh S. A new SV40-based vector developed for cDNA expression in animal cells. J Biochem (Tokyo). 1987 May; 101(5): 1307-10.
Morrison SL, Johnson MJ, Herzenberg LA, Oi VT. Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Proc Natl Acad Sci U S A. 1984 Nov;81(21):6851-5.
Neuberger MS, Williams GT, Fox RO. Recombinant antibodies possessing novel effector functions. Nature. 1984 Dec 13-19;312(5995):604-8.
O'Hare K, Benoist C, Breathnach R. Transformation of mouse fibroblasts to methotrexate resistance by a recombinant plasmid expressing a prokaryotic dihydrofolate reductase. Proc Natl Acad Sci U S A. 1981 Mar;78(3): 1527-31.
Padlan EA. A possible procedure for reducing the immunogenicity of antibody variable domains while preserving their ligand-binding properties. MoI Immunol. 1991 Apr-May;28(4-5):489-98.
Riechmann L, Clark M, Waldmann H, Winter G Reshaping human antibodies for therapy. Nature. 1988 Mar 24;332(6162):323-7.
Roguska MA, Pedersen JT, Keddy CA, Henry AH, Searle SJ, Lambert JM, Goldmacher VS, Blattler WA, Rees AR, Guild BC. Humanization of murine monoclonal antibodies through variable domain resurfacing. Proc Natl Acad Sci U S A. 1994 Feb l ;91(3):969-73.
Shitara K, Nakamura K, Tokutake-Tanaka Y, Fukushima M, Hanai N. A new vector for the high level expression of chimeric antibodies in myeloma cells. J Immunol Methods. 1994 Jan 3;167(l-2):271-8.
Shopes B. A genetically engineered human IgG mutant with enhanced cytolytic activity. J Immunol. 1992 May 1 ;148(9):2918-22.
Strohal R, Kroemer G, Wick G, Kofler R. Complete variable region sequence of a nonfunctionally rearranged kappa light chain transcribed in the nonsecretor P3- X63-Ag8.653 myeloma cell line. Nucleic Acids Res. 1987 Mar 25;15(6):2771.
Studnicka GM, Soares S, Better M, Williams RE, Nadell R, Horwitz AH. Human-engineered monoclonal antibodies retain full specific binding activity by preserving non-CDR complementarity-modulating residues. Protein Eng. 1994 Jun;7(6):805-14.
Thotakura NR, Bahl OP. Enzymatic deglycosylation of glycoproteins. Methods Enzymol. 1987;138:350-9.
Urlaub G, Chasin LA. Isolation of Chinese hamster cell mutants deficient in dihydrofolate reductase activity. Proc Natl Acad Sci U S A. 1980 Jul;77(7):4216-20.
Claims (5)
- 制御性T細胞(Treg)の免疫抑制活性を阻害するCD39抗体を含む、増大した制御性T細胞(Treg)活性に関連付けられる疾病を治療または予防するための、医薬組成物であって、
前記疾病は癌および感染症からなる群から選択される、医薬組成物。 - 前記疾病は、VIH、HBV、HCV、熱帯熱マラリア原虫、または結核菌による感染症からなる群から選択される、請求項1に記載の医薬組成物。
- 前記CD39抗体が、ATPase活性を抑制する、請求項1または2に記載の医薬組成物。
- 前記抗体は、
可変ドメインが、CDR−H1として配列番号2と、CDR−H2として配列番号3と、CDR−H3として配列番号4とからなる群から選択された1つの配列を有する少なくとも1つのCDRを含む重鎖、および/または、
可変ドメインが、CDR−L1として配列番号6と、CDR−L2として配列番号7と、CDR−L3として配列番号8とからなる群から選択された1つの配列を有する少なくとも1つのCDRを含む軽鎖を含む、請求項1から3のいずれか1項に記載の医薬組成物。 - 前記抗体は、
配列番号1に示されるアミノ酸配列を含む重鎖可変領域と、
配列番号5に示されるアミノ酸配列を含む軽鎖可変領域とを含む、請求項1〜4のいずれか1項に記載の医薬組成物。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP08300061.2 | 2008-01-31 | ||
EP08300061 | 2008-01-31 | ||
EP08162683.0 | 2008-08-20 | ||
EP08162683 | 2008-08-20 | ||
PCT/EP2009/051078 WO2009095478A1 (en) | 2008-01-31 | 2009-01-30 | Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014217832A Division JP6041842B2 (ja) | 2008-01-31 | 2014-10-24 | 制御性t細胞活性を抑制するための、ヒトcd39に対する抗体およびその使用 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2011510953A JP2011510953A (ja) | 2011-04-07 |
JP6018361B2 true JP6018361B2 (ja) | 2016-11-02 |
Family
ID=40568778
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010544716A Active JP6018361B2 (ja) | 2008-01-31 | 2009-01-30 | 制御性t細胞活性を抑制するための、ヒトcd39に対する抗体およびその使用 |
JP2014217832A Active JP6041842B2 (ja) | 2008-01-31 | 2014-10-24 | 制御性t細胞活性を抑制するための、ヒトcd39に対する抗体およびその使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2014217832A Active JP6041842B2 (ja) | 2008-01-31 | 2014-10-24 | 制御性t細胞活性を抑制するための、ヒトcd39に対する抗体およびその使用 |
Country Status (8)
Country | Link |
---|---|
US (3) | US20100303828A1 (ja) |
EP (2) | EP2238170B1 (ja) |
JP (2) | JP6018361B2 (ja) |
DK (2) | DK3153526T3 (ja) |
ES (2) | ES2618292T3 (ja) |
HU (1) | HUE032025T2 (ja) |
PT (1) | PT2238170T (ja) |
WO (1) | WO2009095478A1 (ja) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE032025T2 (en) * | 2008-01-31 | 2017-08-28 | Inserm - Inst Nat De La Sante Et De La Rech Medicale | Antibodies to human CD39 and their use to inhibit regulatory T cell activity |
US8865653B2 (en) * | 2010-04-22 | 2014-10-21 | Institut Gustave Roussy | Method of treatment for immunogenic treatment resistant cancer |
PT2647707T (pt) | 2010-11-30 | 2018-11-15 | Chugai Pharmaceutical Co Ltd | Agente terapêutico indutor de toxicidade |
ES2684602T3 (es) * | 2010-12-22 | 2018-10-03 | Orega Biotech | Anticuerpos contra CD39 humano y uso de los mismos |
WO2012178137A1 (en) | 2011-06-24 | 2012-12-27 | Gillies Stephen D | Light chain immunoglobulin fusion proteins and methods of use thereof |
MX2016001356A (es) * | 2013-08-01 | 2016-10-26 | Ludwig Inst For Cancer Res Ltd | Proteina anti-garp y sus usos. |
EP3130606B1 (en) | 2014-04-07 | 2021-10-13 | Chugai Seiyaku Kabushiki Kaisha | Immunoactivating bispecific antibodies |
CA2947157A1 (en) * | 2014-05-13 | 2015-11-19 | Chugai Seiyaku Kabushiki Kaisha | T cell-redirected antigen-binding molecule for cells having immunosuppression function |
EP3215538A4 (en) * | 2014-11-07 | 2018-07-04 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
JP6154415B2 (ja) * | 2015-03-20 | 2017-06-28 | 株式会社三共 | 遊技機 |
JP6154417B2 (ja) * | 2015-03-20 | 2017-06-28 | 株式会社三共 | 遊技機 |
JP6154416B2 (ja) * | 2015-03-20 | 2017-06-28 | 株式会社三共 | 遊技機 |
EP3378488A4 (en) | 2015-11-18 | 2019-10-30 | Chugai Seiyaku Kabushiki Kaisha | METHOD FOR ENHANCING THE HUMORAL IMMUNE RESPONSE |
WO2017086367A1 (ja) | 2015-11-18 | 2017-05-26 | 中外製薬株式会社 | 免疫抑制機能を有する細胞に対するt細胞リダイレクト抗原結合分子を用いた併用療法 |
JP2019509014A (ja) * | 2015-11-23 | 2019-04-04 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Cd39血管アイソフォームターゲティング剤 |
US20190071514A1 (en) * | 2016-03-14 | 2019-03-07 | Innate Pharma | Anti-cd39 antibodies |
ES2912453T3 (es) | 2016-05-06 | 2022-05-26 | Inst Nat Sante Rech Med | Composiciones farmacéuticas para el tratamiento de la leucemia mieloide aguda (LMA) quimiorresistente |
JP7261379B2 (ja) | 2016-06-20 | 2023-04-20 | カイマブ・リミテッド | 抗pd-l1抗体 |
WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
WO2018065622A1 (en) * | 2016-10-07 | 2018-04-12 | Secarna Pharmaceuticals Gmbh & Co Kg | Immunosuppression-reverting oligonucleotides inhibiting the expression of cd39 |
MX2019006897A (es) * | 2016-12-13 | 2019-08-22 | Astellas Pharma Inc | Anticuerpo anti cd73 humana. |
JP2020501589A (ja) * | 2016-12-23 | 2020-01-23 | ウイルツ・バイオロジクス・リミテッド | がんの治療 |
CA3051640A1 (en) * | 2017-03-16 | 2018-09-20 | Innate Pharma | Compositions and methods for treating cancer |
CN111448211B (zh) | 2017-07-31 | 2024-06-07 | 翠舒拉治疗股份有限公司 | 抗cd39抗体、包含抗cd39抗体的组合物和使用抗cd39抗体的方法 |
CA3074588A1 (en) * | 2017-10-06 | 2019-04-11 | Innate Pharma | Restoration of t cell activity via the cd39/cd73 axis |
SG11202002195YA (en) | 2017-11-15 | 2020-04-29 | Innate Pharma | Potentiating the effect of atp release |
MA49796A (fr) | 2017-12-01 | 2020-06-03 | Abbvie Inc | Agoniste du récepteur des glucocorticoïdes et immunoconjugués de celui-ci |
JP7037218B2 (ja) | 2018-03-14 | 2022-03-16 | サーフィス オンコロジー インコーポレイテッド | Cd39と結合する抗体及びその使用 |
AU2019287742A1 (en) * | 2018-06-14 | 2021-01-28 | Antagen Institute For Biomedical Research | Compositions and methods for preventing or reversing T-cell exhaustion through ectonucleotidase inhibition and antibody-mediated target cytosis |
KR20210023983A (ko) | 2018-06-18 | 2021-03-04 | 이나뜨 파르마 | 암을 치료하기 위한 조성물 및 방법 |
WO2020115262A1 (en) | 2018-12-07 | 2020-06-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of cd26 and cd39 as new phenotypic markers for assessing maturation of foxp3+ t cells and uses thereof for diagnostic purposes |
BR112021012685A2 (pt) | 2019-01-11 | 2021-12-28 | Omeros Corp | Métodos para tratar câncer, para aumentar o nível de citocinas th1 nas células mononucleares de sangue periférico humanas, para realçar uma resposta imune antitumoral e para estimular e/ou amplificar uma resposta imune em um sujeito mamífero sofrendo de ou em risco de desenvolver câncer ou metástase de câncer, e, composição farmacêutica |
KR20220050971A (ko) * | 2019-08-27 | 2022-04-25 | 엘피사이언스 (쑤저우) 바이오파마, 엘티디. | 신규 항-cd39 항체 |
KR20220062500A (ko) | 2019-09-16 | 2022-05-17 | 서피스 온콜로지, 인크. | 항-cd39 항체 조성물 및 방법 |
CN110407941B (zh) * | 2019-09-25 | 2020-01-14 | 上海岸迈生物科技有限公司 | Cd39的高亲和力抗体及其用途 |
JP2023521041A (ja) * | 2020-04-03 | 2023-05-23 | トリシュラ セラピューティクス,インコーポレイテッド | 抗cd39抗体と養子細胞療法とを含む併用療法 |
MX2023009100A (es) | 2021-02-03 | 2023-09-25 | Mozart Therapeutics Inc | Agentes aglutinantes y métodos para usar los mismos. |
WO2023076876A1 (en) | 2021-10-26 | 2023-05-04 | Mozart Therapeutics, Inc. | Modulation of immune responses to viral vectors |
WO2023164872A1 (en) * | 2022-03-03 | 2023-09-07 | Arcus Biosciences, Inc. | Anti-cd39 antibodies and use thereof |
TW202340243A (zh) | 2022-03-03 | 2023-10-16 | 美商阿克思生物科學有限公司 | 抗cd39抗體及其用途 |
WO2023201267A1 (en) | 2022-04-13 | 2023-10-19 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
WO2024030956A2 (en) | 2022-08-03 | 2024-02-08 | Mozart Therapeutics, Inc. | Cd39-specific binding agents and methods of using the same |
WO2024115935A1 (en) | 2022-11-29 | 2024-06-06 | Inserm | Methods for the treatment of b-cell lymphoma using cd39 inhibitors |
Family Cites Families (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
AU606320B2 (en) | 1985-11-01 | 1991-02-07 | International Genetic Engineering, Inc. | Modular assembly of antibody genes, antibodies prepared thereby and use |
WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
US5278056A (en) | 1988-02-05 | 1994-01-11 | The Trustees Of Columbia University In The City Of New York | Retroviral packaging cell lines and process of using same |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5660827A (en) | 1992-03-05 | 1997-08-26 | Board Of Regents, The University Of Texas System | Antibodies that bind to endoglin |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
AU6248994A (en) | 1993-02-22 | 1994-09-14 | Rockefeller University, The | Production of high titer helper-free retroviruses by transient transfection |
FR2712812B1 (fr) | 1993-11-23 | 1996-02-09 | Centre Nat Rech Scient | Composition pour la production de produits thérapeutiques in vivo. |
AU701342B2 (en) | 1994-07-13 | 1999-01-28 | Chugai Seiyaku Kabushiki Kaisha | Reconstituted human antibody against human interleukin-8 |
CA2210620C (en) | 1995-01-18 | 2004-06-22 | Boehringer Mannheim Gmbh | Anti-cd 30 antibodies preventing proteolytic cleavage and release of membrane-bound cd 30 antigen |
IL116816A (en) | 1995-01-20 | 2003-05-29 | Rhone Poulenc Rorer Sa | Cell for the production of a defective recombinant adenovirus or an adeno-associated virus and the various uses thereof |
AU5265296A (en) | 1995-04-10 | 1996-10-30 | Universite De Sherbrooke | Atp-diphosphohydrolases, process of purification thereof and process of producing thereof by recombinant technology |
AU690474B2 (en) | 1995-09-11 | 1998-04-23 | Kyowa Hakko Kirin Co., Ltd. | Antibody againts alpha-chain of human interleukin 5 receptor |
US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
AU7071598A (en) | 1997-04-10 | 1998-10-30 | Erasmus University Rotterdam | Diagnosis method and reagents |
GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
EP1573027A4 (en) * | 2001-12-17 | 2007-02-21 | Beth Israel Hospital | METHOD FOR REDUCING ANGIOGENESIS |
DE60334453D1 (de) | 2002-05-30 | 2010-11-18 | Macrogenics Inc | Cd16a bindungsproteine und verwendung zur behandlung von immunkrankheiten |
US20050037382A1 (en) | 2003-04-08 | 2005-02-17 | Robson Simon C. | Methods and compositions for treating and preventing autoimmune disorders |
US20060002932A1 (en) * | 2004-06-04 | 2006-01-05 | Duke University | Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity |
WO2006113237A2 (en) * | 2005-04-18 | 2006-10-26 | Metabolex, Inc. | Cd39l3 and its role in diabetes |
WO2006111986A1 (en) * | 2005-04-19 | 2006-10-26 | Fondazione Santa Lucia I.R.C.C.S. | Method for the detection and the isolation of immunosuppressive regulatory t cells and uses thereof |
ES2427646T5 (es) | 2005-05-09 | 2017-08-22 | Ono Pharmaceutical Co., Ltd. | Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos |
MX2007015942A (es) | 2005-07-01 | 2008-03-07 | Medarex Inc | Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada. |
JP2010533495A (ja) | 2007-07-16 | 2010-10-28 | ジェネンテック, インコーポレイテッド | ヒト化CD79b抗体およびイムノコンジュゲートならびにそれらの使用 |
US20090028857A1 (en) | 2007-07-23 | 2009-01-29 | Cell Genesys, Inc. | Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof |
HUE032025T2 (en) | 2008-01-31 | 2017-08-28 | Inserm - Inst Nat De La Sante Et De La Rech Medicale | Antibodies to human CD39 and their use to inhibit regulatory T cell activity |
PT2242773T (pt) | 2008-02-11 | 2017-09-15 | Cure Tech Ltd | Anticorpos monoclonais para o tratamento de tumores |
EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
HUE034832T2 (hu) | 2008-12-09 | 2021-12-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására |
ES2646863T3 (es) | 2009-11-24 | 2017-12-18 | Medimmune Limited | Agentes de unión específica contra B7-H1 |
KR101791430B1 (ko) | 2009-11-30 | 2017-10-30 | 얀센 바이오테크 인코포레이티드 | 이펙터 기능이 제거된 항체 Fc 돌연변이체 |
US8865653B2 (en) | 2010-04-22 | 2014-10-21 | Institut Gustave Roussy | Method of treatment for immunogenic treatment resistant cancer |
AR083847A1 (es) | 2010-11-15 | 2013-03-27 | Novartis Ag | Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40 |
ES2684602T3 (es) | 2010-12-22 | 2018-10-03 | Orega Biotech | Anticuerpos contra CD39 humano y uso de los mismos |
NZ612379A (en) | 2010-12-23 | 2014-10-31 | Janssen Biotech Inc | Active protease-resistant antibody fc mutants |
MX338353B (es) | 2011-04-20 | 2016-04-13 | Medimmune Llc | Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1. |
MX2017006624A (es) | 2014-11-21 | 2017-08-21 | Bristol Myers Squibb Co | Anticuerpos contra cd73 y sus usos. |
JP2019509014A (ja) | 2015-11-23 | 2019-04-04 | イナート・ファルマ・ソシエテ・アノニムInnate Pharma Pharma S.A. | Cd39血管アイソフォームターゲティング剤 |
WO2018065552A1 (en) | 2016-10-06 | 2018-04-12 | Innate Pharma | Anti-cd39 antibodies |
CA3051640A1 (en) | 2017-03-16 | 2018-09-20 | Innate Pharma | Compositions and methods for treating cancer |
CN111448211B (zh) | 2017-07-31 | 2024-06-07 | 翠舒拉治疗股份有限公司 | 抗cd39抗体、包含抗cd39抗体的组合物和使用抗cd39抗体的方法 |
CA3074588A1 (en) | 2017-10-06 | 2019-04-11 | Innate Pharma | Restoration of t cell activity via the cd39/cd73 axis |
SG11202002195YA (en) | 2017-11-15 | 2020-04-29 | Innate Pharma | Potentiating the effect of atp release |
KR20210023983A (ko) | 2018-06-18 | 2021-03-04 | 이나뜨 파르마 | 암을 치료하기 위한 조성물 및 방법 |
-
2009
- 2009-01-30 HU HUE09705212A patent/HUE032025T2/en unknown
- 2009-01-30 DK DK16198909.0T patent/DK3153526T3/da active
- 2009-01-30 US US12/863,461 patent/US20100303828A1/en not_active Abandoned
- 2009-01-30 WO PCT/EP2009/051078 patent/WO2009095478A1/en active Application Filing
- 2009-01-30 JP JP2010544716A patent/JP6018361B2/ja active Active
- 2009-01-30 EP EP09705212.0A patent/EP2238170B1/en active Active
- 2009-01-30 EP EP16198909.0A patent/EP3153526B1/en active Active
- 2009-01-30 DK DK09705212.0T patent/DK2238170T3/en active
- 2009-01-30 ES ES09705212.0T patent/ES2618292T3/es active Active
- 2009-01-30 PT PT97052120T patent/PT2238170T/pt unknown
- 2009-01-30 ES ES16198909T patent/ES2848323T3/es active Active
-
2014
- 2014-10-24 JP JP2014217832A patent/JP6041842B2/ja active Active
-
2015
- 2015-11-12 US US14/939,650 patent/US10662253B2/en active Active
-
2020
- 2020-05-21 US US16/880,835 patent/US11685792B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
HUE032025T2 (en) | 2017-08-28 |
EP3153526B1 (en) | 2020-09-23 |
EP2238170A1 (en) | 2010-10-13 |
ES2848323T3 (es) | 2021-08-06 |
US11685792B2 (en) | 2023-06-27 |
ES2618292T3 (es) | 2017-06-21 |
WO2009095478A1 (en) | 2009-08-06 |
JP2015057405A (ja) | 2015-03-26 |
US20160137747A1 (en) | 2016-05-19 |
US10662253B2 (en) | 2020-05-26 |
PT2238170T (pt) | 2017-02-21 |
US20210032367A1 (en) | 2021-02-04 |
JP2011510953A (ja) | 2011-04-07 |
EP3153526A1 (en) | 2017-04-12 |
DK3153526T3 (da) | 2020-12-14 |
JP6041842B2 (ja) | 2016-12-14 |
DK2238170T3 (en) | 2017-02-27 |
US20100303828A1 (en) | 2010-12-02 |
EP2238170B1 (en) | 2016-11-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11685792B2 (en) | Antibodies against human CD39 and use thereof for inhibiting T regulatory cells activity | |
US20210261686A1 (en) | Antibodies against human cd39 and use thereof | |
US10273306B2 (en) | Antibodies directed against ICOS for treating graft-versus-host disease | |
JP7333104B2 (ja) | B7-h3に対するモノクローナル抗体および細胞治療におけるその使用 | |
JP2022130393A (ja) | 抗ctla4-抗pd-1二機能性抗体、その医薬組成物および使用 | |
US9637546B2 (en) | PD-1 antibodies and PD-L1 antibodies and uses thereof | |
EP4039710A2 (en) | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 | |
US20150147344A1 (en) | BTLA Antibodies and Uses Thereof | |
JP2018531913A (ja) | ネクチン−4に対する特異性を有する抗体及びその使用 | |
KR20140033037A (ko) | Icos에 대한 항체 및 이의 용도 | |
JP2018522568A (ja) | ヒト化抗ccr7受容体抗体 | |
EP4039704A1 (en) | Anti-pd-1 antibody and use thereof | |
CN114075289A (zh) | 抗cd73的抗体及其用途 | |
CN115812081A (zh) | 抗ctla-4抗体及其用途 | |
CN116323671A (zh) | 具有增加的选择性的多靶向性双特异性抗原结合分子 | |
TW201927336A (zh) | 細胞毒性t細胞耗竭用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20110803 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130702 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130930 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131007 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131030 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131129 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140624 |
|
RD02 | Notification of acceptance of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7422 Effective date: 20141024 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20141024 |
|
RD03 | Notification of appointment of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7423 Effective date: 20141205 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150313 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20150401 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160406 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160808 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160930 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6018361 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |